Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ganaxolone
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Marinus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
Details : Through the acquisition, Immedica strengthens it's global rare disease business by adding Ztalmy (ganaxalone). It is indicated for the treatment of seizures associated with CDKL5 deficiency disorder.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 30, 2024
Lead Product(s) : Ganaxolone
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Marinus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Pegzilarginase
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : KKR
Deal Size : Undisclosed
Deal Type : Acquisition
Kkr and Impilo Announce Strategic Partnership in Rare Disease Platform Immedica Pharma
Details : KKR and Impilo will support Immedica’s growth, including launching the approved ultra-orphan drug Loargys (pegzilarginase) and continuing in-licensing and M&A activities.
Product Name : Loargys
Product Type : Large molecule
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : Pegzilarginase
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : KKR
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
